Media

First patient enrolled in Oncopeptides’ glioblastoma study

Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Vicore Pharma to Present at the Jefferies Global Healthcare Conference